KRAS and neoplasm: Several investigators have assessed circulating tumor DNA (ctDNA) in the blood of mCRC patients during anti-EGFR therapy and found that undetectable low-frequency KRAS-mutant clones may be selected by anti-EGFR treatment [54,55,56,57].